Jatenzo Adolescent (12-17) Dosing: What Clinicians and Families Should Know

Is Jatenzo FDA-Approved for Adolescents?

No. The FDA approved Jatenzo (oral testosterone undecanoate) in March 2019 specifically for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone 1. The label explicitly states that safety and efficacy have not been established in males younger than 18 years.

The key phase 3 trial by Swerdloff et al. enrolled 166 hypogonadal men aged 18 to 65 and demonstrated that 87% of patients achieved eugonadal serum testosterone concentrations (300 to 1 to 100 ng/dL) by the end of the 12-week treatment period 2. No adolescents were included in the study population. Any use in the 12 to 17 age group is therefore off-label, guided by clinical judgment, published case experience, and extrapolation from adult pharmacokinetic data.

Off-label prescribing of testosterone in adolescent males with confirmed hypogonadism is well-established in clinical practice, though the standard formulations used historically have been intramuscular testosterone cypionate or enanthate 3. Oral testosterone undecanoate offers an alternative route that avoids injections, which may improve adherence in teenage patients.

How Adolescent Testosterone Dosing Differs from Adult Protocols

Adolescent testosterone replacement is not a scaled-down version of adult therapy. It is a fundamentally different clinical exercise. The goal in an adult is to restore testosterone to a steady physiological range. In a teenager with hypogonadism, the goal is to mimic the gradual tempo of normal puberty.

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy recommends that testosterone induction in adolescent males begin at low doses and increase incrementally over 3 to 4 years to replicate normal pubertal progression 3. Starting with a full adult replacement dose risks accelerating bone maturation beyond chronological age, causing premature epiphyseal fusion and compromising final adult height 4.

With injectable testosterone, this graduated approach typically starts at 50 mg intramuscularly every 4 weeks, increasing by 50 mg every 6 to 12 months until a full adult dose of 100 to 200 mg every 2 weeks is reached. Translating this principle to Jatenzo means that clinicians who choose oral testosterone undecanoate for an adolescent generally start at the lowest available capsule strength (158 mg once or twice daily) rather than the standard adult starting dose of 237 mg twice daily 1. The dose is then increased based on serum testosterone trough levels, clinical response, bone age advancement, and pubertal progression.

Starting Dose and Titration for Adolescents

For an adolescent male aged 12 to 17 with confirmed hypogonadism (morning serum testosterone consistently below 264 ng/dL on two separate measurements, with an identified etiology), the approach to Jatenzo dosing typically follows this pattern.

Initial assessment. Before prescribing, the clinician confirms the diagnosis with at least two morning serum total testosterone measurements, plus LH and FSH to distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism 3. Karyotype analysis may be indicated for primary hypogonadism (e.g., Klinefelter syndrome, 47,XXY). A baseline bone age radiograph of the left hand and wrist is obtained and compared to chronological age 5.

Starting dose. Published guidance on oral testosterone undecanoate in adolescents is limited. Clinicians extrapolating from both the adult Jatenzo label and the pubertal induction principle commonly initiate therapy at 158 mg once daily with a fat-containing meal. This delivers a substantially lower testosterone exposure than the adult starting dose of 237 mg twice daily, aligning with the goal of gradual virilization 1.

Titration. Serum testosterone trough levels (drawn in the morning, before the daily dose) are checked at 2 to 4 weeks. If levels remain below 300 ng/dL and the clinical response is insufficient, the dose may be increased to 158 mg twice daily. Subsequent increases to 237 mg twice daily follow the same monitoring cadence. Total daily doses above 474 mg are not recommended by the FDA label even for adults. The Endocrine Society advises dose adjustments every 6 to 12 months during pubertal induction, aiming to reach full adult replacement over approximately 3 to 4 years 3.

The fat requirement matters. Jatenzo relies on lymphatic absorption. Without adequate dietary fat at the time of dosing (at least 15 to 20 grams), bioavailability drops significantly 2. Adolescent patients and their caregivers need explicit dietary counseling. A meal with peanut butter, eggs, or avocado is sufficient. Skipping meals or taking capsules on an empty stomach may produce erratic serum levels.

Monitoring Requirements Specific to Adolescent Patients

Monitoring for an adolescent on testosterone replacement involves more parameters than for an adult patient. The following schedule reflects current clinical consensus, drawn from the Endocrine Society guideline and the Jatenzo prescribing information 1 3.

Serum testosterone. Trough levels at weeks 2 to 4 after each dose change. Target range during early induction may be lower than the adult eugonadal range; clinicians often aim for 200 to 400 ng/dL in the first year, increasing the target as the patient advances through puberty.

Hematocrit. Testosterone stimulates erythropoiesis. The Jatenzo label carries a boxed warning about increased risk of major adverse cardiovascular events (MACE), and polycythemia is a known class effect. Hematocrit should be checked at baseline, at 3 months, and then every 6 to 12 months. A hematocrit exceeding 54% warrants dose reduction or temporary discontinuation 1.

Bone age. A left hand and wrist radiograph at baseline, then every 6 to 12 months during treatment. If bone age advances more than 1 year beyond chronological age within a 6-month treatment period, dose reduction or a treatment pause should be considered 4. This is the single most important monitoring parameter unique to adolescent use.

Liver function. Hepatotoxicity with oral testosterone is historically associated with 17-alpha-alkylated androgens, not with testosterone undecanoate. The Jatenzo formulation avoids first-pass hepatic metabolism through lymphatic absorption 6. Baseline liver enzymes (ALT, AST) are still recommended, with repeat testing at 3 to 6 months.

Lipid panel. Testosterone therapy can lower HDL cholesterol. Lipids at baseline and 6 to 12 months are standard 3.

Tanner staging and growth velocity. Documented at each visit. The goal is progression through Tanner stages at a pace consistent with physiologic puberty, not acceleration. Growth velocity should be tracked on standard growth charts.

Growth Plates and Final Height: The Central Risk

The most consequential risk of testosterone therapy in any patient with open epiphyses is premature closure of the growth plates. Testosterone is aromatized to estradiol, and estradiol is the primary hormone responsible for epiphyseal fusion 7. Even modest testosterone doses can accelerate skeletal maturation if growth plates are still open.

A 14-year-old boy with Klinefelter syndrome and a bone age of 12 years has significant remaining growth potential. Starting testosterone at full adult doses could fuse his growth plates within 1 to 2 years, potentially costing several centimeters of final adult height. The graduated dosing approach exists specifically to protect this height potential.

Conversely, an older adolescent (age 16 to 17) with a bone age of 16 and near-complete epiphyseal fusion has less height at stake. In such cases, clinicians may advance the dose titration more quickly, sometimes starting at 158 mg twice daily with plans to reach adult replacement doses within 12 to 18 months rather than 3 to 4 years 3.

The clinical decision depends on the ratio of bone age to chronological age, the remaining predicted growth, and the urgency of virilization. This is why pediatric endocrinology involvement is considered standard of care for adolescent testosterone initiation.

When Clinicians Consider Jatenzo Over Injectable Testosterone for Teens

Injectable testosterone cypionate has been the default formulation for adolescent hypogonadism for decades. It is inexpensive, well-characterized, and available generically. So why would a clinician choose Jatenzo?

Needle avoidance. Some adolescents refuse injections or develop significant anxiety around intramuscular administration. Oral dosing removes this barrier entirely. Adherence data in adolescents specifically on Jatenzo do not yet exist, but studies across other chronic conditions consistently show that oral formulations improve adherence in pediatric populations 8.

Pharmacokinetic profile. Intramuscular testosterone cypionate produces supraphysiologic peaks within 24 to 48 hours of injection, followed by a trough before the next dose. These swings can cause mood instability, energy fluctuations, and acne flares. Jatenzo, taken twice daily, produces a more stable serum testosterone profile throughout the day, which may be preferable during adolescence when mood regulation is already a concern 2.

Self-administration independence. A 16-year-old can take an oral capsule with breakfast and dinner without needing a parent or clinician to administer an injection. This supports age-appropriate autonomy.

The tradeoffs are real, though. Jatenzo is substantially more expensive than generic testosterone cypionate. Insurance coverage for off-label pediatric use may be denied. The twice-daily dosing requirement, paired with the need for dietary fat at each dose, adds complexity that some adolescents will struggle with.

Mental Health Monitoring During Adolescent Testosterone Therapy

Testosterone therapy in adolescents carries psychiatric considerations that extend beyond the adult risk profile. The Endocrine Society guideline recommends monitoring for mood changes, aggression, and behavioral shifts at each visit during testosterone induction 3.

Delayed puberty itself is associated with elevated rates of depression, anxiety, and social withdrawal 4. Many adolescents experience significant psychological improvement once virilization begins. But the hormonal shifts of testosterone induction can also precipitate mood instability in susceptible individuals.

Clinicians should screen for depression and anxiety at baseline and at each follow-up visit using validated instruments such as the PHQ-A (Patient Health Questionnaire for Adolescents). A structured mental health assessment is especially important in the first 6 months of therapy when hormonal fluctuations are greatest.

Dr. Richard Swerdloff, who led the key Jatenzo adult trial, noted in the 2020 JCEM publication that oral testosterone undecanoate produced "a more physiologic testosterone profile compared with injectable formulations" 2. While this observation was made in adult subjects, a more stable hormonal environment could theoretically benefit adolescent mood stability compared to the peaks and troughs of intramuscular injections.

Contraindications and Cautions Specific to Adolescents

The FDA label for Jatenzo lists several contraindications that apply to all patients: breast cancer, known or suspected prostate cancer, pregnancy or potential pregnancy exposure, and hypersensitivity to the active ingredient 1. For adolescents, additional cautions apply.

Constitutional delay of growth and puberty (CDGP). This is the most common cause of delayed puberty in boys. It is self-limited. The Endocrine Society guideline states that short courses of low-dose testosterone (3 to 6 months) may be offered to boys with CDGP for psychological benefit but are not required for eventual pubertal completion 3. Full testosterone replacement is inappropriate for CDGP.

Fertility considerations. Exogenous testosterone suppresses gonadotropin secretion and spermatogenesis. In adolescents with secondary (hypogonadotropic) hypogonadism, gonadotropin therapy (hCG with or without FSH) may be preferred if fertility preservation is a priority 9. This distinction should be discussed with the patient and family before initiating any form of testosterone.

Cardiovascular risk. The Jatenzo label carries a boxed warning for MACE risk based on adult data. Cardiovascular risk in healthy adolescents is generally low, but clinicians should assess family history of premature cardiovascular disease and monitor blood pressure and lipids throughout treatment 1.

Baseline hematocrit above 50% is a relative contraindication. Blood pressure consistently above the 95th percentile for age, sex, and height warrants evaluation before starting therapy.